Literature DB >> 20701864

Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt.

Kenneth C Earhart1, Nasr M Elsayed, Magdi D Saad, Larisa V Gubareva, Ahmed Nayel, Varough M Deyde, Ali Abdelsattar, Ahmad S Abdelghani, Bruce R Boynton, Moustafa M Mansour, Hala M Essmat, Alexander Klimov, Deidra Shuck-Lee, M R Monteville, Jeffrey A Tjaden.   

Abstract

In December 2006, three human specimens were received that were suspected positive for influenza A(H5N1). The specimens were tested using real time PCR. And the presence of A(H5N1) virus was confirmed in 2 patients (16F and 26M), The NA sequence from A(H5N1) positive specimens collected before and after antiviral therapy revealed a mutation (N294S) (N295S according to N1 numbering), previously associated with resistance to oseltamivir. When tested with NA inhibition assays, the two N294S viruses from Egypt exhibited from 57 to 138-fold reduction in susceptibility to oseltamivir, depending on the assay. To our knowledge, this is the first time oseltamivir resistance has been detected in A(H5N1) infecting a human prior to treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20701864     DOI: 10.1016/j.jiph.2009.04.004

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  29 in total

1.  Diversifying evolution of highly pathogenic H5N1 avian influenza virus in Egypt from 2006 to 2011.

Authors:  E M Abdelwhab; Abdel-Satar Arafa; Jürgen Stech; Christian Grund; Olga Stech; Marcus Graeber-Gerberding; Martin Beer; Mohamed K Hassan; Mona M Aly; Timm C Harder; Hafez M Hafez
Journal:  Virus Genes       Date:  2012-06-05       Impact factor: 2.332

2.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Adjuvant efficacy of mOMV against avian influenza virus infection in mice.

Authors:  Byeong-Jae Lee; Sang-Ho Lee; Min-Suk Song; Philippe Noriel Q Pascua; Hyeok-il Kwon; Su-Jin Park; Eun-Ha Kim; Arun Decano; Se Mi Kim; Gyo Jin Lim; Doo-Jin Kim; Kyu-Tae Chang; Sang-Hyun Kim; Young Ki Choi
Journal:  J Microbiol       Date:  2013-10-31       Impact factor: 3.422

Review 4.  Fitness of neuraminidase inhibitor-resistant influenza A viruses.

Authors:  Tatiana Baranovich; Robert G Webster; Elena A Govorkova
Journal:  Curr Opin Virol       Date:  2011-10-01       Impact factor: 7.090

Review 5.  Epidemiology, ecology and gene pool of influenza A virus in Egypt: will Egypt be the epicentre of the next influenza pandemic?

Authors:  E M Abdelwhab; Ahmed S Abdel-Moneim
Journal:  Virulence       Date:  2015       Impact factor: 5.882

6.  Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.

Authors:  Yi Lu; Taijiao Jiang
Journal:  Protein Cell       Date:  2013-04-15       Impact factor: 14.870

7.  Molecular characterization of avian influenza H5N1 virus in Egypt and the emergence of a novel endemic subclade.

Authors:  Rabeh El-Shesheny; Ahmed Kandeil; Ola Bagato; Asmaa M Maatouq; Yassmin Moatasim; Adam Rubrum; Min-Suk Song; Richard J Webby; Mohamed Ahmed Ali; Ghazi Kayali
Journal:  J Gen Virol       Date:  2014-04-10       Impact factor: 3.891

Review 8.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

9.  Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Authors:  Elena A Govorkova; Tatiana Baranovich; Patrick Seiler; Jianling Armstrong; Andrew Burnham; Yi Guan; Malik Peiris; Richard J Webby; Robert G Webster
Journal:  Antiviral Res       Date:  2013-02-28       Impact factor: 5.970

10.  Effectiveness of esterified whey proteins fractions against Egyptian Lethal Avian Influenza A (H5N1).

Authors:  Soad H Taha; Mona A Mehrez; Mahmoud Z Sitohy; Abdel Gawad I Abou Dawood; Mahmoud M Abd-El Hamid; Walid H Kilany
Journal:  Virol J       Date:  2010-11-19       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.